Search jobs 01-Mar-2021 Two Day Online Seminar: Ensuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices - March 18-19, 2021 - ResearchAndMarkets.com
ResearchAndMarkets.com s offering.
Federal regulation of the advertising and promotion of pharmaceuticals and medical devices reflects an aggressive attitude on the part of the regulators that demands, in turn, that industry be keenly aware of the legal and regulatory duties, as well as key recent trends in enforcement activities by the Federal Government. This course will explore in detail what FDA requires of drug and device firms as well as recent current hot buttons in FDA enforcement activity for the advertising arena.
To embed, copy and paste the code into your website or blog:
On January 13, District of Columbia Mayor Muriel Bowser signed the False Claims Amendment Act of 2020 (the Amendment), which expanded liability under the D.C. False Claims Act (D.C. FCA) to encompass tax-related claims. The Amendment is effective unless Congress jointly disapproves it during a 30-day review period. The Amendment endeavors to increase tax revenue for the District of Columbia by enabling the D.C. attorney general to bring a new category of D.C. FCA cases and to incentivize private citizen whistleblowers to file more
qui tam complaints. D.C. now joins New York and Illinois in taking the novel step of expanding its FCA to apply to tax fraud an expansion that, if successful, could become a wave of the future and create heightened exposure for tax liability for many businesses and individuals. [1]
Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
Introduction
In December 2020, California Attorney General Xavier Becerra was
announced to be President-Elect Joseph R. Biden, Jr. s
pick to lead the Department of Health and Human Services. The
California Attorney General s Office is the second largest
Justice Department in the United States, second only to the U.S.
Department of Justice, and California Attorney General Xavier
Becerra was the first Latino Attorney General in California s
history. Before becoming the Attorney General of California,
Becerra had a 24-year career in the U.S. House of
Representatives.
1 In 2017, Governor Jerry Brown
appointed Becerra to the last two years of Kamala Harris s term
Regulatory permissions: FCA reminds firms to use or cancel
DB pension transfer advice: FCA Assessment Tool and latest data analysis
FCA MoU with DWP and MaPS
Consumer investments data review 2020: FCA summary
CMC charges for financial products and services claims: FCA CP21/1
FCA Regulation round-up
UK Regulators Network: second publication of performance scorecards
EU economic and financial system: European Commission Communication on further steps to foster openness, strength and resilience
IFD: EBA final reports on draft RTS on risk takers and variable remuneration
FICOD: Joint Committee of ESAs final report on draft ITS on reporting of intragroup transactions and risk concentration